-
Posted by
Two Blokes Apr 20 -
Filed in
Stock
-
2 views
It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (ABBV 0.62%). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to failed its clinical trials.
